Selective Nanoparticulate Systems for Drug Delivery in Inflammatory Bowel Disease
Pharmaceutics · 31.12.2025 · 18 (1) · 55
DOI: 10.3390/pharmaceutics18010055 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 31.12.2025. Verfasst von Alberta Ribeiro und 1 weiteren Autor:innen. Beteiligte Einrichtung: IUCS-University Institute of Health Sciences, Cooperativa de Ensino Superior Politécnico e Universitário (CESPU), Rua Central de Gandra, 1317, 4585-1…. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 161 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cooperativa de Ensino Superior Politécnico e Universitário, CESPU—Cooperativa de Ensino Superior Politécnico e Universitário Crl.
Abstract (Originalsprache)
Inflammatory bowel disease is a result of inappropriate continuous non-specific inflammation in the intestinal tract, which in turn is aggravated by defects in the activation of the mucosal immune system and in the barrier function of the intestinal epithelium. The most prominent manifestations of IBD are ulcerative colitis (UC) and Crohn’s disease (CD). UC is characterized by a continuous pattern that commonly starts with lesions in rectum mucosa and is contained in the colon. On the other hand, CD affects the ileum and colon in a discontinuous pattern, and the lesions are often transmural. Conventional therapies often face limitations such as systemic side effects, poor drug stability, and low site-specificity. In recent years, nanoparticle (NP) systems have emerged as a promising strategy to overcome these challenges, offering improved targeting, controlled release, and enhanced therapeutic efficacy. Several studies have shown that the preferential accumulation of NPs in the inflamed colon is influenced by the pathophysiological changes associated with IBD, including alterations in transit time, pH value, enzymatic activity, microbial composition, and mucus integrity. These disease-specific characteristics provide unique opportunities to design smart and responsive NPs that enhance drug delivery and therapeutic efficacy while minimizing systemic exposure. This work presents an overview of novel technologies based on nanosystems, with the ability to specifically target the affected areas of the GI tract in inflammatory bowel disease.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- IUCS-University Institute of Health Sciences, Cooperativa de Ensino Superior Politécnico e Universitário (CESPU), Rua Central de Gandra, 1317, 4585-116 Gandra, Portugal.
- UNIPRO-Oral Pathology and Rehabilitation Research Unit, University Institute of Health Sciences (IUCS), Cooperativa de Ensino Superior Politécnico e Universitário (CESPU), Rua Central de Gandra, 1317, 4585-116 Gandra, P…
- i3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal.
ORCID-Profile: Alberta Ribeiro, Rute Nunes
Förderung
- Cooperativa de Ensino Superior Politécnico e Universitário
- CESPU—Cooperativa de Ensino Superior Politécnico e Universitário Crl
Zitieren
APA
Ribeiro, A., & Nunes, R. (2025). Selective Nanoparticulate Systems for Drug Delivery in Inflammatory Bowel Disease. Pharmaceutics, 18(1), 55. https://doi.org/10.3390/pharmaceutics18010055
Vancouver
Ribeiro A, Nunes R. Selective Nanoparticulate Systems for Drug Delivery in Inflammatory Bowel Disease. Pharmaceutics. 2025;18(1):55. doi:10.3390/pharmaceutics18010055
BibTeX
@article{Ribeiro2025,
author = {Ribeiro, Alberta and Nunes, Rute},
title = {Selective Nanoparticulate Systems for Drug Delivery in Inflammatory Bowel Disease},
journal = {Pharmaceutics},
year = {2025},
volume = {18},
number = {1},
pages = {55},
doi = {10.3390/pharmaceutics18010055}
}
EUVIMED